Guido Würth
Head of Corporate Development & Radiopharma Medical & Health; Sales; Operations Affibody AB
Guido Wuerth joined Affibody AB in 2021 and leads Corporate Development for the company’s radiopharmaceutical portfolio, overseeing development strategy, asset positioning, and partnering activities. Previously, he held senior leadership roles at MorphoSys, serving as Global Program Head and contributing to the U.S. approval of tafasitamab (MONJUVI®) and multiple out-licensing transactions. Earlier, he led Global Clinical Operations at Sandoz and served as Global Program Medical Director for the etanercept biosimilar Erelzi®, with extensive regulatory experience. Guido has also held senior positions at Baxter, Antisense Pharma, and Schwarz Pharma (now UCB). He is a board-certified urologist and holds an MD from the University of Cologne, Germany.
Seminars
- Clinical translation underway: First-in-human Phase 1 study of HER2-targeted radioligand moving forward with dose escalation
- Expanding the therapeutic window: Protein mass-dose optimization to address HER2-low disease
- Broadening the radiopharma space: Addressing physiological HER2 expression to unlock new RLT opportunities
